Hospital Adoption Nozin's Nasal Sanitizer is trusted by hundreds of hospitals and healthcare professionals, indicating strong market validation and a ready-made path to expand infection prevention programs and MRSA/MSSA risk mitigation across additional facilities.

MRSA Programs The NOVA programs are specifically designed for MRSA/MSSA colonization risk mitigation, presenting a clear opportunity to position Nozin as a core component of infection prevention bundles in hospitals, surgical centers, and long-term care facilities.

Safety Partnerships Recent collaborations and recognition, including The Leapfrog Group engagement, highlight alignment with safety and quality initiatives; leverage these credentials in procurement discussions and RFPs to differentiate Nozin's value proposition.

Network Expansion With a lean team and mid-market revenue profile, Nozin can scale through hospital distributors, GPOs, and regional networks to broaden reach within health systems and outpatient settings seeking standardized nasal decolonization protocols.

Cost Savings Position Nozin as a high value, long acting antiseptic that reduces infection risk and lowers overall infection-related costs, supported by clinical evidence of high germ kill rates and broad-spectrum efficacy.